Ensuring success in AAV scale-up: key data from case studies across four serotypes

In this webinar, we explore key considerations and best practices for scaling AAV production, including selecting a transient transfection cell line and scale-up strategies for rAAV processes.

Data from small-scale case studies across four AAV serotypes demonstrate:
• scale-up of an rAAV9 process at 50 L and 200 L scale with yields of < 2 × 10¹¹ vg/mL
• low hcDNA (including encapsidated)
• post-affinity chromatography yields of < 18 ng/10¹⁴ vg

Leave with a roadmap for process scale-up in single-use bioreactor systems along with insights into choosing the best tools and cell lines for your application and serotype.

Watch this webinar to:
• Gain knowledge of rAAV production process development
• Learn how to best approach process scale-up
• Understand why cell line selection is key to success

Want to learn more about the Xcellerex™ X-platform single-use bioreactor? Head over to https://info.cytivalifesciences.com/x-platform-for-vv-manufacturing.html